Gilead Sciences (GILD) Starts Phase 2 Clinical Trial Evaluating GS-7340 for HIV
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Join SI Premium – FREE
Gilead Sciences, Inc. (Nasdaq: GILD) announced the initiation of a Phase 2 clinical trial evaluating GS-7340 for the treatment of HIV-1 infection in treatment-naïve adults. GS-7340 is a novel prodrug of tenofovir, the active agent in Viread® (tenofovir disoproxil fumarate). In previous studies, GS-7340 has demonstrated the ability to provide greater antiviral efficacy at a dose that is ten times lower than Viread.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hanmi Pharm licenses obesity drug to Genentech in $2.3B deal
- Elroy Air wins $46M U.S. Army contract for cargo drone system
- Faraday Future signs robotics distributor deal, plans partner event
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
